Metabolomics Study on Intensive Care Acquired Muscle Weakness in Polytrauma

Completed

• Conditions: Metabolomics; Critical Illness Myopathy; Critical Care; Critical Illness; Critical Illness Polyneuropathy; Intensive Care (ICU) Myopathy; Muscle Weakness

• Registration Number: NCT03819959
• Lead Sponsor: Technical University of Munich

Brief Summary

In this mono-center pilot trial, polytrauma patients admitted to intensive care will be included. Investigators are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing.

Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-01-19
• Study First Submitted QC: 2019-01-24
• Study First Posted: 2019-01-29
• Study Start: 2019-03-24
• Primary Completion: 2020-04-22
• Study Completion: 2020-04-22
• Status Verified: 2020-10
• Last Update Submitted: 2020-10-04
• Last Update Posted: 2020-10-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• acute polytrauma patient
• age ≥ 18 years old
• expected intensive care stay ≥ 3 days
• American Society of Anesthesiologists classification I or II

Exclusion Criteria

• patient had received cardiopulmonary resuscitation
• limitation of therapy or comfort care

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Metabolomics	a median of 14 days	Blood Metabolome will be isolated from blood samples. All samples will be screened for changes in the blood metabolome during muscle wasting (i.e. Intensive Care Unit Acquired Weakness) using mass spectrometry

Secondary Outcome Measures

Name	Time	Method
Muscle histology	a median of 14 days	Immunohistochemistry will be done in muscle samples. All samples will be screened for changes in the muscular structure and correlation with blood metabolome changes.
Phosphoproteomics	a median of 14 days	Phosphoproteomics will be done in muscle samples using mass spectrometry. All samples will be screened for influence of muscular changes (i.e. Intensive Care Unit Acquired Weakness (ICUAW)) and correlation with blood metabolome changes.

Trial Locations

Locations (1)

Klinikum rechts der Isar, School of Medicine, Technical University of Munich; 🇩🇪 Munich, Bavaria, Germany